文献速递鼻科

揭示吸烟对过敏性鼻炎的影响:疾病严重程度与皮下免疫治疗疗效

Unveiling the Impact of Smoking on Allergic Rhinitis: Disease Severity and Efficacy of Subcutaneous Immunotherapy.
PubMed 文献 · Otolaryngol Head Neck Surg · 2024-08-10

这项开放观察性队列研究纳入505例接受尘螨过敏原皮下免疫治疗(SCIT)的过敏性鼻炎(AR)患者,按吸烟状态分为从不吸烟、既往吸烟和当前吸烟三组。研究发现三组基线AR严重程度相似,当前吸烟者第一年SCIT疗效感知较低,且SCIT结束后及结束后2年改善率较低,但三年长期疗效三组相当。

要点

  • 当前吸烟者第一年SCIT疗效感知较从不吸烟者低(P < .05)。
  • 当前吸烟者SCIT结束后及结束后2年改善率较低(P < .05)。
  • 三组基线AR严重程度及三年长期SCIT疗效相似(P > .05)。

核心结论

  • 不同吸烟状态的AR患者基线疾病严重程度和长期SCIT疗效相似。
  • 主动吸烟与哮喘风险增加、早期SCIT疗效感知延迟、3年内改善减少及SCIT后2年获益减少相关。
  • 及时戒烟对减轻这些影响至关重要。

研究设计与样本

  • 开放观察性队列研究,纳入505例接受尘螨过敏原SCIT的AR患者,分为从不吸烟、既往吸烟和当前吸烟三组。
  • 研究地点为三级转诊中心。

主要发现

  • 与从不吸烟者相比,既往吸烟者和当前吸烟者中男性、饮酒和哮喘的比例更高(P < .05)。
  • 当前吸烟者过敏性结膜炎患病率高于既往吸烟者(P < .05)。
  • SCIT前,即使调整混杂因素后,三组AR严重程度相似(P > .05)。
  • 当前吸烟者第一年SCIT疗效报告较低(P < .05)。
  • 到第三年时,三组长期疗效相当(P > .05)。

临床怎么用

  • 作者认为及时戒烟对减轻主动吸烟对SCIT疗效的不利影响至关重要。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the impact of smoking statuses on disease severity and subcutaneous immunotherapy (SCIT) efficacy in allergic rhinitis (AR). STUDY DESIGN: Open observational cohort study. SETTING: Tertiary referral center. METHODS: Five hundred and five AR patients undergoing dust mite allergen SCIT were categorized into never smokers, former smokers, and current smokers. AR severity was assessed using widely employed questionnaires. The changes in questionnaire scores pre- and post-SCIT were evaluated for SCIT efficacy. The differences in disease severity and SCIT efficacy were compared for different smoking statuses among AR patients. RESULTS: Compared to never smokers, former and current smokers exhibited higher proportion of male, alcohol, and asthma (P < .05). Current smokers had a greater prevalence of allergic conjunctivitis than former smokers (P < .05). Before SCIT, AR severity was similar across 3 groups, even after adjusting for confounders (P > .05). Current smokers reported lower SCIT efficacy in the first year (P < .05). By the third year, 3 groups showed comparable long-term efficacy (P > .05). However, current smokers experienced a significant decrease in benefits 2 years post-SCIT (P < .05) and lower improvement rates at the end of the 3-years SCIT period and 2 years following SCIT (P < .05). CONCLUSION: AR patients across different smoking statuses demonstrated similar baseline disease severity and long-time SCIT efficacy. Active smoking was associated with increased asthma risk, delayed early SCIT efficacy perception, reduced improvement over 3 years, and diminished benefits 2 years after SCIT. Prompt smoking cessation is crucial to mitigate these effects.

来源:Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Yuan X, Liu L, Zhang B, et al. Unveiling the Impact of Smoking on Allergic Rhinitis: Disease Severity and Efficacy of Subcutaneous Immunotherapy. Otolaryngol Head Neck Surg. 2024. PMID: 39126287. doi:10.1002/ohn.937

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。